Drugs and FDA
FDA approves giredestrant combination for certain advanced breast cancers
The FDA approved giredestrant with everolimus for adults with certain ESR1-mutated, ER-positive, HER2-negative advanced breast cancers.

The FDA approved giredestrant (Wilserdly) with everolimus on November 16, 2026, for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The cancer must have recurred during or after endocrine-based adjuvant therapy, or progressed on at least one endocrine-based regimen for metastatic disease. The FDA also authorized the FoundationOne Liquid CDx assay to identify patients with ESR1 mutations.
Efficacy was assessed in the evERA Breast Cancer trial, which included 373 adults, 207 of whom had tumors with ESR1 mutations. In that group, median progression-free survival was 10 months with giredestrant and everolimus, compared with 5.5 months with physician-selected endocrine therapy and everolimus. The FDA reported a statistically significant improvement.
Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis and nausea. The prescribing information includes warnings about bradycardia and embryo-fetal toxicity.


